Autism är en neuropsykiatrisk störning som hör till autismspektrumstörning (AST). Vid autism är den sociala kommunikationen och repetitiva sensoriska-motoriska beteenden bristfällig. Autism är 3–4 gånger vanligare hos pojkar än hos flickor. För att diagnostisera autism finns det huvudsakligen två system; DSM- och ICD-systemet. Idag finns ingen godkänd farmakologisk behandling för indikationen autism. Ett ämne som har studerats de senaste åren som potentiell behandling vid autism är oxytocin. Oxytocin är ett neuropeptidhormon som produceras i hypotalamus och brukar benämnas som “lugn och ro-hormonet”. Syftet med denna litteraturöversikt är att undersöka om intranasal oxytocin har någon effekt vid autismsymtomen hos barn 0–19 år. sitet. Ingen av studierna visade signifikant förbättring på det repetitiva beteendet. Ett flertal studier visade en signifikant förbättring i social kommunikation hos patienter som fått intranasal oxytocin, medan andra studier inte tydde på någon signifikant förbättring. Oxytocin förbättrade signifikant förmågan att läsa av känslor från andras ögon utifrån ögonkontakt. Majoriteten av biverkningarna på grund av användning av oxytocin var lindriga.Slutsatsen som dras är att oxytocin kan vara en intressant substans för behandling av autism, åtminstone för social kommunikation. Oxytocin gav biverkningar, majoriteten i form av lindriga biverkningar. Studierna visar olika resultat på förbättring av kommunikation hos autism därmed behövs det ytterligare studier med ett större urval för att kunna stärka resultaten. Även fler studier behövs för att kontrollera om oxytocin kan förbättra repetitiva beteendet eftersom denna litteraturstudie visade motstridiga resultat.

No description available.

Background: Contraceptives for men has existed for centuries. However, the only contraceptives available for men are condoms, withdrawal during sexual intercourse or undergoing Vas occlusion. The issues currently with these methods are that many couples are not comfortable with using condoms and vasectomy is a non-reversible contraceptive as it requires surgery. Currently, only research has been made with regards to hormonal contraceptives for men. The basis for hormonal contraceptives for men is that it disturbs hypothalamic-pituitary–gonadal axis, by suppressing GnRH, LH and FSH in order to suppress spermatogenesis. The substances that have been clinically tested as a potential hormonal contraceptive for men are androgens, androgens together progestins and synthetic androgens. Aim: The aim of this thesis was to examine the effectiveness of the substances that have been used in past and recent clinical trials and the adverse drug reactions/effects. Method: Results from the clinical trials were collected through PubMed with regards to preordained criteria, which resulted in 18 scientific articles being used in the results. Results: Overall, the results showed that the majority of substances used in previous and recent clinical trials are effective in suppressing spermatogenesis. The results also showed that a majority of substances used in previous and recent clinical trials had severe adverse drug effects severe amongst the participants. Discussion and Conclusion:  In summary, the research shows that amongst the substances used in recent and current clinical trials, that synthetic androgens have the best potential as a hormonal contraceptive for men with regards to effectiveness and adverse drug effects.

No description available.

Bakgrund: Alzheimers sjukdom (AD) är neurodegenerativ och kännetecknas framför allt av det tidiga symtomet minnesförlust. De patologiska skadorna i hjärnan utmärks av senila plack och neurofibrillära nystan (NFTs). Senila plack består av peptiden amyloid-b (Ab) och NFTs innehåller proteinet tau. Ab har länge stått i fokus när det kommer till patogenesen vid AD och forskning kring behandlingsstrategier mot sjukdomen har länge riktat sig mot denna peptid, men än så länge utan lyckade resultat. Mer fokus har riktats till tau och i nuläget finns det ett antal tau-riktade behandlingsstrategier under utveckling och tau-immunoterapi är en av dessa. Syfte: Idag finns det inte någon behandling som botar AD vilket betyder att det är viktigt att hitta nya behandlingsstrategier mot sjukdomen. Tidigare studier tyder på att tau är ett potentiellt mål för behandling mot AD och syftet med detta arbete var därför att undersöka om tau-immunoterapi är en möjlig behandlingsstrategi vid AD. Metod: Sekundärdata samlades in från databasen PubMed. Datan granskades och bedömdes som användbar eller inte. Detta resulterade i att sju orginalartiklar valdes till arbetet, sex studier i djurmodeller och en klinisk studie.  Resultat: Studierna i djurmodellerna visade att tau-immunoterapi reducerade patologiskt tau och i hälften av studierna observerades även en förbättring av de kliniska symtomen. Den kliniska studien visade att AADvac1 är säkert och ansågs vara en lovande kandidat för vidare studier. Slutsats: Resultaten från studierna visar att tau-immunoterapi är en lovande behandlingsstrategi vid AD. Trots detta krävs det fler kliniska studier som undersöker tau-immunoterapi för att säkerställa om behandlingen har någon klinisk effekt på patienter med AD eller inte.

Background: Statins are among the most used drugs in Sweden. There are currently four statins available on the Swedish market; atorvastatin, simvastatin, pravastatin and rosuvastatin. Statins act by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme-A reductase, also known as HMG-CoA-reductase. HMG-CoA-reductase is the rate-limiting enzyme of the cholesterol synthesis. Decreased hepatic cholesterol leads to increased low-density lipoprotein (LDL) clearance from plasma to liver cells. Having a high level of LDL cholesterol is potentially dangerous as it can lead to atherosclerosis and cardiovascular disease. Statins significantly reduce cardiovascular morbidity and mortality in patients with and without coronary heart disease. Purpose: The aim of this work was to investigate if there are any differences between the different statins according to contemporary evidence. Method: This is a literary analysis. Studies included were searched from PubMed. A total of five studies were included. Results: The result of this study indicates rosuvastatin to be most efficacious in lowering LDL cholesterol (LDL-C), triglycerides and total cholesterol. It also improved the high-density lipoprotein cholesterol (HDL-C) better than atorvastatin, simvastatin and pravastatin. Study 1 showed rosuvastatin to lower LDL-C with statistical significance (P<0.001) across dose ranges (10-40 mg) after 12 weeks. Study 2 compared a dose ratio of 1:2 between rosuvastatin and simvastatin in lowering LDL-C with a 3.24% (95% CI 4.10 to 2.38) favor of rosuvastatin. Study 4 compared effects of atorvastatin 80 mg and rosuvastatin 20 mg in patients with ST elevation myocardial infarction in a 4-week therapy. Rosuvastatin 20 resulted in a 35% compared with atorvastatin 80 mg 34% (P=0.59) reduction in LDL-C levels. Study 1 demonstrated rosuvastatin to improve HDL-C levels in daily doses of 40 mg with statistical significance compared with atorvastatin, simvastatin and pravastatin. Study 1 demonstrated rosuvastatin to lower total cholesterol with statistical significance (P<0.002) across doses compared with atorvastatin, simvastatin and pravastatin. Study 1 also demonstrated rosuvastatin to lower triglycerides more. In daily doses of 40 mg rosuvastatin had a statistical significance (P<0.002) versus simvastatin and pravastatin, but not atorvastatin. The P value between rosuvastatin and atorvastatin was not mentioned, neither the P-value between atorvastatin, simvastatin and pravastatin. Conclusion: Statins are not equipotent. Rosuvastatin showed greater results in reducing LDL-C, triglycerides and total cholesterol with no increased risk of adverse events compared with atorvastatin, simvastatin and pravastatin. Rosuvastatin still lacks in clinical experience which makes needs for further studies on this topic.

Achondroplasia and hypochondroplasia are two forms of skeletal dysplasias caused predominantly by single base mutations in the fibroblast growth factor receptor 3 gene (FGFR-3). The mutation for achondroplasia is a G1138A/C substitution and the mutation for hypochondroplasia (occurring about 50% of the time) is a C1620A/G substitution. Recent genetic studies have shown that spontaneous mutations for achondroplasia and hypochondroplasia occur exclusively on the paternally derived chromosome, suggesting that these mutations occur preferentially during spermatogenesis. For unknown reasons, the mutation rates at these FGFR-3 nucleotides appear to occur at a much higher frequency than nucleotide specific mutation rates observed in other human genetic diseases. The purpose of this study was to develop an assay that could detect the frequencies of achondroplasia and hypochondroplasia causing mutations in human sperm. A Needle-in-a-Haystack PCR/RE/LCR selection technique has been developed that measures single base changes, commonly single base substitution mutations, at sensitivities of one mutant allele in one cell in up to 10⁷ wild-type cells. This technique was modified and designed for the achondroplasia and hypochondroplasia base sites 1138 and 1620 of the FGFR-3 gene. With the development of this technique, future studies could focus on determining the frequencies of the mutations in the sperm of fathers of affected children and the frequencies of the mutations in the sperm of the normal population. These studies will help elucidate the paternal age effect, have important implications in genetic counseling and provide a novel method by which to study genetic disease in humans.

Acute laminitis is a severely debilitating disease of the laminae of the equine digit; however, the mechanism(s) of pathogenesis have yet to be fully elucidated. In physiologic states, the endothelium synthesizes substances, such as nitric oxide (NO; vasodilator) and endothelin-1 (ET-1; profound vasoconstrictor), which play a crucial role in vasomotor regulation. The overall hypothesis is that the initiating factor in the onset of acute laminitis is a disruption in the balance between NO and ET-1, which leads to digital vasoconstriction and subsequent laminar ischemic necrosis. In vitro studies with digital vessels from healthy horses and horses with naturally-acquired laminitis determined that ET-1 caused concentration-dependent, sustained contraction of arteries and more profound contraction of veins, and incubation with the nonselective ET receptor antagonist (PD145065) at a 10-5 M concentration abolished these contractile effects. ET-1 was then administered into the digit of healthy conscious horses, which resulted in reduced blood flow and the ET antagonist, especially in combination with a NO donor, reversed these reductions. Naturally-acquired laminitic horses had a trend for increased jugular and cephalic venous plasma ET-like immunoreactivity, and horses during the development of black walnut extract (BWE)-induced laminitis developed increased digital venous plasma ET-like immunoreactivity. After validation for equine tissues, ET-1 immunohistochemical staining was conducted on digital vascular and laminar tissues, but no notable differences were found between healthy and naturally-acquired or experimentally-induced laminitic horses. During the developmental stages of BWE-induced laminitis, digital blood flow initially decreased followed by hyperemia, corresponding with demonstration of clinical signs of laminitis. Administration of the ET antagonist, and the antagonist combined with a NO donor, improved Starling force alterations by improving digital vascular resistances and blood flow. Utilizing digital vessel rings from BWE-treated horses, ET-1 caused a concentration-dependent contraction in vitro that was abolished by the ET antagonist. Endothelium-dependent vasodilation was decreased in these vessels, demonstrating possible altered endothelial function due to BWE administration. Based on the results of these studies, ET-1 appears to play a role in the pathophysiology of acute laminitis in horses and continued investigations evaluating ET antagonists as preventative and therapeutic agents for this devastating disease are warranted.

Gastrointestinal tract disease is the leading natural cause of death in horses and horses with ischemic intestinal disease have the greatest mortality. We hypothesized there is basal synthesis of endothelin-1 (ET-1) in the intestinal tract of healthy horses that is likely involved in regulating vasomotor tone, secretion and motility and that ET-1 synthesis increases with gastrointestinal tract disease, which may be involved in the pathophysiology of these disorders. Plasma ET-like immunoreactivity was increased in horses with naturally-acquired gastrointestinal disease, compared with normal horses; values were greatest in horses with large intestinal strangulation obstruction, enterocolitis and peritonitis. There was an association between ET-1 levels and survival, PCV and duration of signs of pain. Immunohistochemical staining for ET-1 was present in surface epithelium, villi, muscularis and serosa of numerous intestinal segments in healthy horses. Staining was also present in submucosal vessels with veins staining more intense than arteries. Staining appeared more diffuse and intense in samples from horses with intestinal strangulation obstruction. Polymerase chain reaction analysis revealed the presence of ET-1 gene expression in numerous intestinal segments of normal horses. These findings suggest ET-1 is involved in physiologic functions such as regulation of secretion, vasomotor tone and motility, and that increased ET-1 with strangulation obstruction may be involved in the pathophysiology of these disorders. ET-1 caused sustained, concentration-dependent increases in cecal longitudinal smooth muscle tone in vitro, but the magnitude of contraction was less than that induced by carbachol. Pre-incubation of tissues with ETA (BQ-123) and ETB (IRL-1038) receptor antagonists alone did not inhibit ET-1 induced contraction. However, contractile responses were inhibited when tissues were incubated with both antagonists (10-5 M) together, suggesting both ETA and ETB receptors mediate the contraction. Electric field stimulation did not change the contractile response. These studies indicate a physiologic role of ET-1 in the equine gastrointestinal tract and that increased synthesis and release occurs with gastrointestinal tract disease, especially ischemic conditions, and may contribute to the pathophysiology of these disorders. Further studies involving ET-1 and ET antagonists appear warranted.

Although curable in the majority of cases, Diffuse Large B-cell Lymphoma (DLBCL), the most prevalent Non-Hodgkin Lymphoma (NHL) throughout the world, is still fatal for 30-40% patients. This patient population could benefit from the addition of new drugs to the current DLBCL chemotherapy regimen. Histone deacetylase inhibitors (HDIs) are a promising group of drugs for the treatment of hematological malignancies. In the current study we tested the HDI PXD101 in a panel of the two most common DLBCL subtypes, GCB (germinal center) and ABC (activated B-cell like), ABC being the least curable subtype. Cell viability assays showed that PXD101 induces antiproliferative effects at submicromolar concentrations in DLBCL cell lines regardless of DLBCL subtype. Flow cytometry demonstrated that upon PXD101 treatment two GCB cell lines (DB and OCILY19) undergo G2M cell cycle arrest followed by apoptosis, while two GCB (SUDHL4 and SUDHL8) and one ABC (U2932) cell line undergo G1 arrest with little apoptosis. Further experiments demonstrated that upon PXD101 removal G1-arresting cells recover their normal proliferative state, while in G2M-arresting cells only 8h exposure to PXD101 is sufficient to induce considerable apoptosis. We classified as PXD101-resistant cell lines that re-enter the cell cycle after drug removal, and PXD101-sensitive cell lines that commit to apoptosis after short periods of drug exposure. Kinase assays established that upon PXD101 treatment G1 phase cyclin dependent kinase 2 (CDK2)-cyclin E complex activity significantly decreases in resistant but not in sensitive cells lines. Furthermore, pull-down assays revealed that CDK inhibitors (CDKIs) p21 and/or p27 in resistant, but not sensitive cell lines persistently bind the CDK2-cyclin E complex throughout PXD101 treatment, thereby explaining why resistant lines stop at the G1 phase. CDKIs induction by PXD101 was p53-independent. This is the first time that an in vitro model of sensitivity and resistance to HDIs in DLBCL is established. We have also performed preliminary genomic and proteomic analysis in DLBCL cell lines treated with PXD101. We anticipate that further analysis of the genomic response and the functional impact of protein acetylation induced by HDIs will offer additional insight into mechanisms of sensitivity and resistance to HDIs in DLBCL.